We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Neuartige Hormontherapien beim fortgeschrittenen Prostatakarzinom.
- Authors
Sigle, August; Gratzke, Christian; Grabbert, Markus
- Abstract
The systemic treatment of advanced prostate cancer (PCa) has undergone an absolute revolution in the past decade. Numerous new substances have been approved for all stages of advanced disease and treatment has been increasingly intensified. The focus continues to be on substances with an effect on the androgen receptor axis. In this review, approved treatment options for metastatic hormone-sensitive PCa (mHSPC), non-metastatic castration-refractory PCa (nmCRPC) and metastatic castration-refractory PCa (mCRPC) are summarized. A special focus is on novel hormone therapeutic agents. Based on recent trial data, potential triple combinations for mHSPC as well as treatment sequence options and novel targeted agents for mCRPC are also highlighted.
- Publication
Die Urologie, 2023, Vol 62, Issue 5, p529
- ISSN
2731-7064
- Publication type
Article
- DOI
10.1007/s00120-023-02081-w